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1. Introduction 
Alzheimer’s disease (AD) is an incurable terminal neurodegenerative disorder primarily 
affecting the elderly. Even after a century of intensive investigation, its pathogenic 
mechanism still remains enigmatic. Many hypotheses have been advanced to interpret the 
disease pathogenesis; however none are able to provide an integrated mechanistic view that 
can unify the numerous superficially disconnected aspects of AD etiology and pathology. 
Extracellular amyloid plaques and intracellular neurofibrillary tangles are the two 
prominent hallmarks of AD neuropathology. It remains unclear what pathogenic events link 
aggregated proteins such as amyloid beta peptides (Aβ) and/or phosphorylated tau to 
neuronal damage and death. It is also important to know more precisely how advancing age 
triggers the disease pathogenesis and how other modifiers affect the disease process. The 
absence of this basic knowledge is a major barrier not only for understanding of the disease 
but also for development of effective AD therapies. 
Autophagy, or specifically macroautophagy, is a subcellular process participating in 
membrane trafficking and intracellular degradation and functions in the turnover of 
damaged organelles and unfavorable proteins through the lysosomal machinery. The 
autophagy-lysosomal system plays an important role in maintaining intracellular 
homeostasis and also participates in the pathophysiology of many diseases including cancer, 
infectious and neurodegenerative diseases (Mizushima et al., 2008). Abnormal autophagic 
structures have been reported to be extensively involved in AD pathology in brains of 
human patients as well as animal models (Nixon et al., 2005; Shacka et al., 2008). However, it 
remains unclear how autophagy contributes to the disease.  
Numerous review papers are available that summarize the current knowledge regarding the 
molecular and cellular aspects of autophagy and its extensive involvement in various 
diseases. In this chapter, we focus on the concept of an “autophagy-lysosomal cascade” as a 
key mechanistic insight into AD pathogenesis. This disease hypothesis is based on recent 
work from our laboratory as well as growing evidence from other AD research groups. The 
autophagy-lysosomal cascade hypothesis has the capability to integrate many seemingly 
disconnected aspects of AD pathophysiology into a common cellular framework. We believe 
that further characterization of the details of autophagic participation in AD will be 
important for development of anti-Alzheimer’s therapies. 
2. Autophagy-derived Alzheimer’s pathogenesis: Signs, lesions and causes 
Autophagy-lysosomal involvement in AD and other related animal models has been 
extensively documented. However, it remains enigmatic if autophagy plays a causative role 
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or is a consequence of the disease process. It is also unclear if autophagy is protective or 
detrimental with respect to the disease pathogenesis. AD has a multifactorial etiology and 
also exhibits heterogeneous pathological signs. Correspondingly, numerous disease 
hypotheses have been proposed primarily based on one or few particular pathological 
features; currently, no hypothesis can provide a unified mechanistic connection to the 
hierarchical changes in AD pathogenesis. Practically, an accurate disease mechanism is 
expected to be attributable to different aspects of the disease etiology and also interpretable 
to the development of different pathological features of the disease. Here we introduce an 
autophagy-lysosomal cascade in AD pathogenesis and discuss how this pathogenic cascade 
is initiated by or contributes to the different aspects of the causes, the signs and the lesions 
of AD pathophysiology. 
2.1 Granulovacuolar degeneration and autophagy-lysosomal neuropathology 
Granulovacuolar degeneration (GVD) along with plaques and tangles are the earliest 
described and also the most prominent histopathologic signs of AD (Anderton, 1997; Ball, 
1982; Burger & Vogel, 1973; Funk et al., 2011; Okamoto et al., 1991). Granulovacuolar 
structures were initially reported for AD in 1911. They are characterized as large translucent 
vacuoles containing electron-dense granule cores appearing in cytoplasm (Shacka et al., 2008) 
and are often found in pyramidal neurons of the hippocampus. GVD bodies are double 
membrane enclosed partially digested cytoplasmic contents (Okamoto et al., 1991), suggesting 
an autophagic origin for the GVD. This autophagic association is further confirmed by positive 
immunostaining for LC3 and p62 (autophagic markers), LAMP1 (lysosome-associated 
membrane protein 1) and CHMP2B (charged multivesicular body protein 2B) to the GVD 
bodies (Funk et al., 2011; Yamazaki et al., 2010). These studies suggest that the GVD bodies are 
enlarged vesicles derived from autophagy and endocytosis. GVD may also appear in the 
normal aging brains where plaques and tangles are sparse (Anderton, 1997).  
One of the earliest pathological signs observed in patients with AD is the appearance of 
numerous enlarged autophagic and endosomal vesicles accumulating in perikarya, neurites 
and synaptic terminals (Nixon et al., 2005; Nixon et al., 2008; Shacka et al., 2008) due to 
defective autophagy-lysosomal degradation. The defect was initially thought to result from a 
putative blockage of vesicle fusion among autophagosomes, endosomes and lysosomes thus 
leading to the failure for autophagosomes to acquire lysosomal catabolic enzymes necessary 
for cargo digestion (Boland et al., 2008; Nixon, 2007; Nixon et al., 2005; Yu et al., 2005). This 
view was primarily based on distinguishing autophagosomes in electron micrographs. The 
identification of pre- and post-lysosomal autophagic or endosomal vesicles in electron 
micrographs may be misleading. Distinct types of vesicles can dynamically fuse with each 
other and thus form diverse highly polymorphic structures.  These heterogeneous vesicles are 
hard to be identified with certainty, especially when compromised as part of the disease 
process. Failure of lysosomal acidification was also proposed as an alternative mechanism 
responsible for defective autophagic degradation (Lee et al., 2010). By direct expression of 
human Aβ1-42 in Drosophila brains, we found that some dysfunctional autophagic vesicles have 
clearly fused with lysosomes and are acidified (Ling et al., 2009). Thus the massive 
accumulation of autophagy-lysosomal vesicles in brains apparently results from the vesicular 
storage of indigestible cargo including Aβ1-42 aggregates and other contents. Lysosomal-
derived secondary lesions caused by the vesicular leakage of the autophagy-lysosomal 
contents into cytosol may further activate autophagy and exacerbate vesicle accumulation as 
discussed in the next section.  
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Direct Aβ1-42 expression in Drosophila brains induces age-dependent neurodegeneration 
through an autophagy-lysosomal injury (Ling et al., 2009). Many degenerative neurons exhibit 
typical granulovacuolar features (Fig. 1), reflecting the reliability of the Drosophila model as an 
important tool to dissect AD pathogenic mechanisms. In addition to the prominent GVD, the 
neuronal autophagy-lysosomal machinery may also contribute to the development of amyloid 
plaques (our unpublished observation) as well as other disease-associated phenotypes such as 
tangle formation, neurite atrophy, synapse loss, etc as discussed in the following sections. 
Taken together, autophagy-lysosomal involvement in AD is an early histopathologic sign that 
has been well recapitulated in different animal models of AD. 
 
 
Fig. 1. The GVD morphology recapitulated in a Drosophila AD model with neuron-limited 
expression of human Aβ1-42. (A) A normal morphology of neuronal soma. (B) An affected 
neuron accumulates numerous autophagy-lysosomal vesicles. (C) Extensive 
neurodegeneration occurs with GVD feature. (D) A higher magnification of view of the 
neuronal soma in the square area in (C). Arrowheads, autophagy-lysosomal vesicles; N, 
nuclei. Scale bars = 1μm. 
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2.2 The pathogenic lesions of AD are a result of the autophagy-lysosomal injury 
AD exhibits heterogeneous features in its clinical symptoms, histopathology and 
neurochemistry. Besides the GVD discussed above, other well-documented 
neuropathological changes include widespread neuron loss, extracellular plaques, 
intraneuronal tangles, Hirano bodies, defective mitochondria, neurite atrophy, synapse loss, 
calcium dyshomeostasis, oxidative stress, neuroinflammation, cerebral amyloid angiopathy, 
etc. The cause-effect relationships between or among these changes have never been clearly 
established. To clarify the cause-effect relationships among these changes related to 
neuronal autophagy, we classify them here as pathological signs or pathogenic lesions. A 
pathological sign is defined as any detectible pathological event not resulting in additional 
downstream pathological events; whereas a pathogenic lesion is defined as any detectible 
pathological event causing other downstream pathological events. Previously we proposed 
a central role of autophagy-lysosomal system in AD pathogenesis (Ling & Salvaterra, 2009). 
Here we discuss how a primary autophagy-lysosomal injury in neurons might sit at the top 
of a pathogenic hierarchy and initiate the secondary and tertiary lesions such as 
mitochondrial dysfunction, oxidative stress, intracellular Ca2+ dyshomeostasis, membrane 
and organelle damage, all of which eventually develop into the plethora of heterogeneous 
neuropathologic signs including neurological defects, extracellular diffuse Aβ deposition, 
amyloid plaques, intracellular tangles, Hirano bodies, neurite and synapse atrophy, 
extensive neuronal death, etc.  
2.2.1 Amyloid deposition and autophagy-lysosomal machinery 
A widely held view is that Aβ is produced via APP proteolysis at the surface of neuronal 
cytoplasmic membranes and released into extracellular spaces. Diffusely distributed 
extracellular Aβ then assembles into toxic oligomers, aggregates and eventually condenses 
into senile plaques over a long period of time (Armstrong, 1998; Marchesi, 2005; Torp et al., 
2000). However, emerging evidence has demonstrated that a large fraction of Aβ is 
generated in intracellular compartments rather than at cell surfaces (Gouras et al., 2005; 
LaFerla et al., 2007). Several subcellular loci have been suggested for intracellular Aβ 
production including rough endoplasmic reticulum (ER), Golgi apparatus, endosomes, 
autophagosomes and lysosomes. However, it is unclear how intracellular Aβ is 
subsequently transported to extracellular spaces and how Aβ deposits into the focal 
amyloid plaques (Fiala, 2007; Gouras et al., 2005). 
The intracellular Aβ may be sequestered by autophagy-lysosomal machinery along with 
damaged organelles where Aβ is generated. We previously showed that autophagy-
sequestered Aβ1-42, in turn, decreases the capacity of autophagy-lysosomal degradation 
(Ling & Salvaterra, 2011a; Ling et al., 2009). Aβ1-42-induced dysfunction of lysosomal vesicles 
may retain indigestible Aβ1-42 along with Aβ1-40. In support of this possibility, highly 
concentrated intracellular Aβ has been identified in various autophagic and endosomal 
vesicles (Petanceska et al., 2000; Takahashi et al., 2002). Autophagy-lysosomal compartments 
also function in secretion (Gerasimenko et al., 2001; Griffiths, 2002; Luzio et al., 2007; 
Manjithaya & Subramani, 2011; Pfeffer, 2010). It is plausible therefore that some of 
lysosomal vesicles may secret their stored monomeric or oligomeric Aβ peptides into 
extracellular spaces. Consistent with this, some early observations showed that Aβ is 
secreted by intracellular secretory compartments (Probst et al., 1991; Rajendran et al., 2006). 
Highly concentrated Aβ1-42 aggregates stored in enlarged autophagy-lysosomal vesicles may 
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contribute to the development of amyloid plaques during aging or neurodegeneration (our 
unpublished observation). Thus the neuronal autophagy-lysosomal pathway appears to 
play a central role in amyloid deposition associated with either AD or normal brain aging. 
2.2.2 Lysosome-derived chemical lesions and subcellular damage 
Aβ (especially Aβ1-42) is an amphipathic molecule known to disturb biological membranes 
(Eckert et al., 2010; Gibson Wood et al., 2003). The membranes of lysosome-related vesicles 
with an acidic microenvironment are especially sensitive to Aβ disturbance (Ditaranto et al., 
2001; McLaurin & Chakrabartty, 1996). This membrane disruption is thought to result from 
the direct interaction between the hydrophobic C-terminus of Aβ peptides and the lipid 
bilayer of the membrane (Marchesi, 2005). The interaction also appears to be important for 
membrane-associated Aβ assembly into higher ordered structures (Friedman et al., 2009; 
Sureshbabu et al., 2010). Compromised membrane integrity greatly increases membrane 
conductance that has been attributed to a putative ionic channel formed by Aβ peptides 
(Jang et al., 2010).  
Aβ1-42 expressed in Drosophila brains induces a deterioration and compromise of autophagy-
lysosomal vesicles (Ling et al., 2009). The vesicle compromise and subsequent leakage is a 
primary causative event that results in secondary pathogenic lesions as evident by extensive 
membrane disruption occurring in cytoplasmic, nuclear and other organelle membranes. In 
electron micrographs, disrupted membranes are discontinuous with large gaps or exhibit 
irregularly multilamellar or indistinct cloud-like morphology (Fig. 2), suggesting that 
membrane disruption results from structural destabilization likely due to an altered 
intracellular microenvironment rather than direct interaction between Aβ1-42 and lipid 
bilayers. Furthermore, affected neurons are consistently associated with cytoplasmic 
acidification. Because numerous autophagy-lysosomal vesicles are dramatically enlarged 
and retained in affected neurons, once their membranes are compromised, a leakage of their 
contents will significantly alter the chemical microenvironment of the cytosol causing an 
intraneuronal chemical lesion. Thus the autophagy-lysosomal injury may be the cause of 
multiple downstream pathogenic events (Ling & Salvaterra, 2009; Reddy & Beal, 2008). 
Mitochondrial deficits are a prominent pathogenic lesion in AD (Moreira et al., 2010a; 
Moreira et al., 2010b; Reddy & Beal, 2008).  Lysosomal-derived chemical lesions may be the 
proximate cause of these deficits. Electron micrographs show a host of morphological 
changes including decreased size, abnormal cristae and accumulation of osmiophilic 
materials in brain tissues from AD patients (Baloyannis, 2006). These morphological features 
are consistent with our observations using the Drosophila model of AD (Ling et al., 2009). 
Mitochondria provide the energy necessary to support various cellular activities many of 
which are quite demanding in neurons such as active maintenance of ionic gradients. At the 
same time, mitochondria also produce free radicals and other oxidative molecules that are 
intimately involved in the aging process (Balaban et al., 2005). Indeed, metabolic defects, 
energy deficiency and increased oxidative stress are common pathogenic lesions found in 
AD (Baloyannis, 2006). In addition to being the major source of intracellular reactive oxygen 
species, mitochondria are also particularly vulnerable to oxidative damage. Oxidative stress 
may thus result in a self-amplifying pathogenic lesion. Oxidative stress induces additional 
compromise of autophagy-lysosomal and mitochondrial membranes and the later will 
produce more free radicals and further exacerbate the pathogenic lesion. 
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Fig. 2. Aβ1-42 expression causes membrane disruption due to a lysosome-derived chemical 
lesion. (A) The plasma membranes of an affected and adjacent neuronal somas exhibit 
discontinuity (arrows). The arrowhead points to a damaged autophagy-lysosomal vesicle; 
Double arrowheads point to Aβ1-42 aggregate. (B) The plasma and intracellular membranes 
exhibit multilamellar or cloudy morphology (arrows). N, nuclei. Scale bars = 1μm. The 
image in (B) was previously published (Ling et al., 2009). 
Lysosomal-derived chemical lesions may also destabilize membranes of ER, nuclei and 
various transport vesicles that will release Ca2+ into the cytosol. Neuronal Ca2+ is normally 
stored in membrane compartments such as ER, mitochondria, nuclear envelope and 
neurotransmitter vesicles (Verkhratsky & Petersen, 1998). Compromise of these membrane-
bounded organelles results in a loss of homeostatic intracellular Ca2+ control, another 
prominent chemical lesion in AD pathogenesis (LaFerla, 2002; Supnet & Bezprozvanny, 
2010). Cytoplasmic Ca2+ is a pivotal neuronal signal regulating multiple intraneuronal 
activities, neural functions and synaptic plasticity. In vitro application of synthetic Aβ can 
elevate intracellular Ca2+ levels that make cultured neurons more vulnerable to glutamate 
excitotoxicity (Mattson et al., 1992). Disturbances in neuronal Ca2+ may also affect 
mitochondrial function and vesicular trafficking and, in turn, exacerbate the 
neurodegenerative cascade. 
Lysosomal-derived chemical lesions can destabilize the cytoskeleton, a subcellular 
component essential for axonal transport, maintenance of normal structure and function of 
neurites and synapses as well as other cellular activities. Elevated intracellular Ca2+ alone 
was observed to be sufficient to destabilize microtubules and accelerate tau phosphorylation 
(Mattson et al., 1991), thus linking this chemical lesion with the formation of neurofibrillary 
tangles. Lysosomal-derived chemical lesions are also associated with the formation of 
Hirano bodies, rod-shaped and paracrystalline intracellular aggregates composed of actin 
and cofilin (Maciver & Harrington, 1995). Many neurodegenerative conditions induce the 
rapid formation of cofilin-actin rod-like inclusions that occur primarily in axons and 
neurites (Minamide et al., 2000). Cytoskeletal destabilization will disrupt axonal transport of 
mitochondria and neurotransmitter vesicles as well as many other important subcellular 
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activities in neurons (McMurray, 2000; Stokin et al., 2005). Tau hyperphosphorylation and 
microtubule destabilization will also accelerate neurite and synapse atrophy due to the 
crucial role of microtubules in supporting neuronal terminals and maintaining synaptic 
integrity (Harada et al., 1994). Thus lysosomal-derived chemical lesions may initiate 
multiple downstream pathogenic lesions via oxidative stress, Ca2+ aberration, cytoplasmic 
acidification, etc leading to a self-exacerbating and vicious cycle.  
Membrane integrity is essential for implementation of neuronal function because the 
conduction of nerve impulses depends on the maintenance of stable ionic gradients. After 
an electrical signaling event, restoration of active membrane properties requires an intact 
membrane to restore proper ionic gradients. Normal neuronal function also relies on the 
integrity of neurites that extend far from cell bodies. Thus the abnormally elevated Ca2+ 
levels, destabilized microtubules and other cytoskeletal elements, defects in axonal 
transport, degenerating neurites and synapses resulting from lysosome-derived chemical 
lesions will cause a decline in neuronal functional performance that may contribute to 
impairment in the encoding or retrieval of new memories, one of the earliest signs of AD 
(Selkoe, 2002). 
2.2.3 Autophagy-lysosomal injury contributes to neurite and synapse atrophy 
Alzheimer’s dementia is believed to start from synaptic alterations that correlate more 
robustly with cognitive decline, memory loss and neurodegeneration than the traditional 
pathological markers such as plaques and tangles (Selkoe, 2002). Synapse loss and neurite 
atrophy is critically dependent on cortical Aβ levels. Direct expression of Aβ in Drosophila 
neurons is sufficient to induce synaptic neuropathy (Zhao et al., 2010). However it has never 
been clear how Aβ induces synapse and neurite damage. Recent evidence demonstrates that 
neurite atrophy is associated with autophagy activation; and autophagy inhibition protects 
neurites from degeneration (Wang et al., 2006; Yang et al., 2007). Brain traumatic injury 
elevates neuronal autophagy and also exhibits axonal degeneration (Chu et al., 2009), 
supporting an association between the two. Degenerating axons have autophagosome 
accumulation and cytoplasmic vacuolization along with intracellular Ca2+ elevation and 
cytoskeletal alterations (Knoferle et al., 2010), indicating that lysosomal-derived chemical 
lesions may contribute to neurite and synapse degeneration. Consistent with this, 
manipulation of autophagy activity or intracellular Ca2+ levels affects the severity of axonal 
degeneration (Knoferle et al., 2010). In addition, implementation of neuronal function 
intimately relies on endocytic recycling of neurotransmitters and their receptors at synaptic 
terminals. Thus subtle changes in the autophagy-lysosomal system may affect synapse 
construction, maintenance and remodeling (Rowland et al., 2006). 
2.2.4 Widespread neuronal loss and autophagy-derived necrosis  
A major unanswered question in Alzheimer’s pathogenesis is to identify the execution 
pathway responsible for widespread neuronal death. Apoptosis, a well-controlled and self-
regulated programmed cell death, has been widely considered to be the relevant cell death 
mechanism in many neurodegenerative disorders. However, this appealing mechanism is 
problematic when applied to Alzheimer’s pathogenesis (Graeber & Moran, 2002). Apoptosis 
is characterized by DNA fragmentation, chromatin condensation, caspase activation, cell 
shrinking and plasma membrane blebbing. DNA fragmentation detected by the TUNEL 
method is widespread in AD type neuronal death; however apoptotic morphology is rare 
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(Jellinger & Stadelmann, 2000). DNA fragmentation, phosphatidylserine exposure on the 
cell surface as well as mitochondrial dysfunction also exist in other non-apoptotic types of 
cell death, raising the concern that the widely used TUNEL or annexin V staining alone is 
not sufficient to validate apoptosis as a particular cell death mechanism.  
Autophagy, while generally viewed as a cell survival mechanism, is also thought to cause 
autophagic cell death (Bursch, 2001), another type of programmed cell death characterized by 
an abundance of autophagic vesicles in dying cells (Chen et al., 2010). Autophagy over-
activation in Drosophila larval fat body results in a significant cell loss suggesting that this 
pathway is capable of inducing cell death (Scott et al., 2007). Neuronal death after hypoxic and 
ischemic brain injury is also associated with a dramatic increase of autophagic vesicles; 
furthermore, mice with Atg7 deficiency show nearly complete protection from neuronal death, 
suggesting that autophagy plays an essential role in executing neuronal death after hypoxic 
and ischemic injury (Koike et al., 2008). Cellular models for Parkinson’s disease using the 1-
methyl-4-phenylpyridium (MPP+) neurotoxin show that induced autophagic toxicity leads to 
neuronal death (Chu et al., 2007). Even with these observations, it is still controversial whether 
the presence of autophagy morphology is a cause or a result of cell death. 
Either brain aging or Aβ1-42 production causes a chronic deterioration of the neuronal 
autophagy-lysosomal system leading to accumulation of inefficient and enlarged autophagy-
lysosomal vesicles in neurons (Ling & Salvaterra, 2011a). Lysosomal compartments are known 
for membrane permeabilization that release lysosomal cathepsins and other hydrolases into 
the cytosol; however, the process and the extent of the leakage are usually regulable or may 
activate a controlled mode of cell death (i.e. apoptosis) (Boya & Kroemer, 2008; Guicciardi et 
al., 2004). Intriguingly, we found that Aβ1-42-induced lysosomal leakage causes uncontrollable 
intraneuronal necrotic destruction (Ling et al., 2009). Some dying neurons lose their normal 
cytosolic structures but maintain a relatively normal shape for the plasma membrane forming 
balloon cells (Fig. 3). Necrotic cell death usually stimulates a powerful inflammatory response. 
Indeed, neuroinflammation is a prominent pathological feature of AD (Sastre et al., 2011). 
These data indicate that autophagy-derived necrosis is likely to be the primary cell death 
execution pathway responsible for the widespread neuronal loss in AD pathogenesis. 
2.3 Causative connections between AD risk factors and autophagy-lysosomal injury 
The firmly established risk factors of AD are increasing age, the ε4 allele of the 
apolipoprotein E (ApoE) gene, familial history of AD and Down syndrome. Down 
syndrome-associated AD neuropathology is thought to be a consequence of the over dosage 
of the APP gene. Familial history as a risk factor is particularly associated with early-onset 
familial AD and is attributable to various inheritance-acquired mutations predominantly 
located in three genes: APP, PSEN1 and PSEN2 (Bertram & Tanzi, 2008). The ApoE ε4 allele 
is associated with sporadic AD (Bertram & Tanzi, 2008) and may account for 50% of AD 
cases in United States (Raber et al., 2004). Thus among the 4 firmly-established AD 
associated genes, APP, PSEN1 and PSEN2 are causative genes for familial AD; whereas 
ApoE is a susceptibility gene for sporadic AD. Among various AD risk factors, advancing 
age is the most prominent as evident by a dramatically increased prevalence of AD as 
people get older. The incidence of AD in the American population raises from 2% at 65–74 
years old to 19% at 75–84 and 42% or more in individuals over 85 years old (see Alzheimer’s 
Disease Facts and Figures 2007, Alzheimer’s Association). Besides aging, other less 
prominent risk factors include traumatic brain injuries, increased cholesterol levels and 
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other lifestyle and pathophysiological conditions such as high blood pressure, heart disease, 
stroke and diabetes (Flicker, 2010; Lahiri & Maloney, 2010; McDowell, 2001; Martins et al., 
2006; Rosendorff et al., 2007). It is currently unknown how those causative and susceptibility 
genes, aging, various environmental and lifestyle risk factors interact to affect the disease 
onset. Here we consider how the autophagy-lysosomal injury establishes a pathological 
connection between the main etiological factors and AD onset. Other risk factors that could 
also be attributable to AD pathogenesis through direct or indirect connection to the 
autophagy-lysosomal injury are not discussed here due to space limitations.  
 
 
Fig. 3. The morphology of balloon cells results from Aβ1-42-induced neurodegeneration. (A) 
A balloon cell of degenerated neuronal soma surrounded by relatively normal neuronal 
somas. (B-C) Necrotic intracellular destruction causes the formation of balloon cells. (D) A 
balloon cell is electron lucent with partially digested mitochondria and other organelles. 
Stars (*), balloon cells. Scale bars = 1μm. 
2.3.1 Genetic determinants and autophagy-lysosomal Aβ degradation 
Amyloid deposition formed by Aβ aggregates is a pathological hallmark of AD. Familial 
AD-associated mutations on APP, PSEN1 and PSEN2 genes mostly favor production of 
hyperaggregatable Aβ1-42 rather than Aβ1-40. More AD susceptibility loci recently identified 
are also associated with Aβ metabolism (Sleegers et al., 2010). Aβ1-42 in its fibrillary or 
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oligomeric form is believed to be the main causative agent of AD. Aβ overproduction causes 
a dementia-like phenotype in transgenic animals (McGowan et al., 2006). Direct Aβ1-42 
expression in Drosophila brains induces age-dependent neurodegeneration (Finelli et al., 
2004; Iijima et al., 2004; Crowther et al., 2005; Ling et al., 2009), suggesting that 
overproduction of Aβ1-42 alone is sufficient to initiate neurodegenerative cascade. Even 
though Aβ1-42 is the most widely accepted causative agent for AD, brain amyloid load does 
not correlate strictly with the severity of dementia. In an interrupted clinical trial, anti-Aβ 
immuno-therapy resulted in decreased brain amyloidosis but exhibited subtle cognitive 
benefits (Gilman et al., 2005). Furthermore, Aβ is a normal component of serum and 
cerebrospinal fluid in individuals with no disease symptoms. These observations complicate 
the cause-effect relationship between Aβ and AD. However, these seemingly paradoxical 
aspects of Aβ and AD are compatible with the self-exacerbating autophagy-lysosomal 
cascade that is initiated by but then independent of further Aβ1-42 production as discussed in 
the next section. 
Aβ1–42-induced neurodegeneration via an autophagy-lysosomal injury does not conflict with 
the general protective function of the autophagy-lysosomal machinery. The protective or 
detrimental effect of neuronal autophagy is primarily dependent on the efficiency of 
lysosomal degradation of disease-associated aggregate-prone proteins and damaged 
organelles. Not all aggregate-prone proteins are amenable to autophagic degradation (Wong 
et al., 2008). Human Aβ1–40 and Aβ1–42 expressed in Drosophila brain have differential effects 
on neuronal autophagy-lysosomal degradation (Ling et al., 2009). Aβ1–42 induces an age-
dependent functional defect as well as a structural compromise in autophagy-lysosomal 
vesicles. These deteriorated vesicles massively accumulate in affected neurons and their size 
is dramatically enlarged. Aβ1–40, in contrast, does not produce any detectible changes in 
either the neuronal autophagy-lysosomal machinery or neurological defects in animals, 
suggesting that Aβ1–40 may be amenable to autophagic removal and thus lack significant 
neurotoxicity. The differential autophagic responses to Aβ1–40 vs. Aβ1–42 is consistent with 
the paradoxical observations that APP proteolysis primarily generates Aβ1–40 (Hartmann et 
al., 1997), while it is Aβ1–42 that predominantly accumulates in neurons (Gouras et al., 2005). 
The early-onset deterioration of neuronal autophagy-lysosomal machinery specific to Aβ1–42 
but not Aβ1–40 is also consistent with the causative role of Aβ1–42 in AD pathogenesis.  
2.3.2 The risk factors of ApoE and cholesterol 
ApoE and cholesterol, known to have a strong impact on development of cardiovascular 
disease (Purnell et al., 2009), are also important modifiers of AD onset (Lahiri et al., 2004; 
Sambamurti et al., 2004). The underlying mechanism linking ApoE and cholesterol with AD 
pathogenesis is still not completely understood. Cholesterol is a normal membrane 
component that modifies membrane fluidity. Accumulating evidence shows that cholesterol 
modulates Aβ production and aggregation through its effect on lipid rafts. Membrane-
embedded APP undergoes amyloidogenic proteolysis by beta-secretase (BACE1) or non-
amyloidogenic proteolysis by alpha-secretase. Lipid rafts, the cholesterol- and sphingolipid-
enriched membrane microdomains (Simons & Toomre, 2000), play an essential role in 
amyloidogenic APP proteolysis, because the lipid raft enhances accessibility of BACE1 to 
APP (Ehehalt et al., 2003; Rushworth & Hooper, 2010; Vetrivel & Thinakaran, 2010). Lipid 
rafts may also facilitate Aβ aggregation (Rushworth & Hooper, 2010) and extracellular Aβ 
internalization (Lai & McLaurin, 2010). Increased cholesterol accelerates APP localization 
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into lipid rafts and enhances Aβ generation (Kosicek et al., 2010; Michikawa, 2003); 
consistent with observations that elevated dietary cholesterol uptake or 
hypercholesterolemia is associated with increased formation of amyloid plaques (Kivipelto 
et al., 2001). In addition, cholesterol depletion inhibits neuronal Aβ generation (Sambamurti 
et al., 2004); and cholesterol-reducing statin drugs appear to reduce the risk of dementia 
(Gibson Wood et al., 2003).  
ApoE is the major carrier of lipids, including cholesterol, in the brain. Lipidated ApoE has 
been shown to inhibit Aβ transport across blood-brain-barrier and facilitate its degradation 
(Fan et al., 2009). The ε4 allele of ApoE gene was observed to contribute to Aβ deposition 
(Jones et al., 2011; Raber et al., 2004), favor cerebral amyloid angiopathy (Kumar-Singh, 
2008) and promote earlier AD onset (Roses, 1996). So ApoE and cholesterol may affect the 
onset of AD likely through modification of Aβ production and aggregation and thus 
indirectly influence the neuronal autophagy-lysosomal machinery. It is also plausible that 
there is a direct interaction between ApoE/cholesterol and the efficiency of autophagic-
lysosomal turnover as a potential mechanism for the altered risk of AD. ApoE/cholesterol 
modifies membrane fluidity that could directly affect the trafficking of lysosomal vesicles as 
well as their degradation. ApoE in neurons is actively recycled by endocytosis (DeKroon & 
Armati, 2001) but not amenable to intracellular degradation (Rensen et al., 2000). ApoE ε4 
also appears to accentuate abnormal changes in early endosomes at preclinical stages of AD 
(Cataldo et al., 2000), impair endocytosis of extracellular Aβ internalization, prevent 
lysosomal degradation of Aβ (Yamauchi et al., 2002) and increase intracellular Aβ1-42 
accumulation (Yu et al., 2010; Zerbinatti et al., 2006). 
2.3.3 Brain aging and autophagy-lysosomal catabolism 
AD exhibits multiple neuropathological signs and clinical symptoms that distinguish it from 
normal brain aging. However, normal aging brains undergo similar histopathologic changes 
seen in AD including the presence of plaques, tangles, Hirano bodies, GVD, neurite and 
synapse deficit, shrinkage in overall brain volume, decreased  brain weight and enlargement 
of brain ventricles (Anderton, 1997; Drachman, 2007). The differences in these changes 
comparing AD with normal aging appear to be quantitative rather than qualitative (Ball, 
1982). Even after a century of intensive studies, the pathogenic connection between normal 
aging and AD remains elusive.  
Human Aβ1-42 expression in Drosophila brains results in a massive accumulation of enlarged 
dysfunctional autophagy–lysosomal vesicles that become increasingly compromised with 
age leading to deterioration of neuronal integrity and necrotic intraneuronal destruction 
(Ling et al., 2009). Intriguingly, the process of normal aging undergoes similar pathogenic 
changes in wild-type Drosophila brains without expression of any disease-associated proteins 
(Ling & Salvaterra, 2011a). The only difference between Aβ1-42 expression and normal brain 
aging is the time scale of the neuropathological progression. Aβ1-42 induces an early-onset 
autophagy-lysosomal neuropathology which progresses rapidly; whereas normal aging has 
a late-onset neuropathology which progresses at a slower rate. These data are consistent 
with observations that low levels of abnormal autophagy-lysosomal vesicles, characterized 
as typical granulovacuolar degeneration, are also observed in hippocampal neurons from 
brains of mentally normal patients (Ball & Lo, 1977), suggesting that brains normally 
undergo deterioration of the autophagy-lysosomal machinery during aging. Thus normal 
brain aging accompanies neurodegeneration via an autophagy-lysosomal neuropathology 
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that may occur at a slow enough rate or on a small enough scale. Any cognitive decline 
associated with normal aging-associated neurodegeneration will go unnoticed. Consistent 
with this possibility, individuals with normally measured cognitive function undergo an 
age-dependent reduction in overall brain volume and weight as well as an age-dependent 
enlargement of brain ventricles due to neuron loss (Anderton, 1997).  
Autophagy-lysosomal machinery maintains intracellular homeostasis and thus protects 
neurons from degeneration. Basal levels of neuronal autophagy are believed to decrease 
with age (Komatsu et al., 2007); however, direct evidence supporting this view is absent. In 
Drosophila brains autophagy activity during normal aging appears to be stable based on 
observations that no significant changes occurs in expression levels for several autophagy-
related genes (Ling & Salvaterra, 2011b). Moreover, induction of neuronal autophagy in a 
conditional Drosophila model is protective in young animals, but likely detrimental in older 
animals (Ling & Salvaterra, 2011a). Therefore it is reasonable to propose that the autophagy–
lysosomal machinery likely shifts from a functional and protective status to a pathological 
and deleterious status during brain aging. Consistent with this, autophagic function is 
known to decline with age (Bergamini et al., 2007). Taken together, either brain aging or Aβ1-
42 proteotoxicity contributes to the chronic deterioration of the neuronal autophagy-
lysosomal system.  The deterioration of this catabolic machinery appears to be a key 
pathogenic event that converts normal brain aging into pathological aging leading to 
Alzheimer’s neurodegeneration. 
3. Autophagy-lysosomal cascade: A hypothesis for AD pathogenesis 
Remarkable progress has been made in studying many aspects of AD.  Unfortunately, this 
has not resulted in the successful development of effective treatments, primarily because of 
the absence of a definite pathogenic mechanism. Numerous hypotheses have been advanced 
to address AD pathogenesis including the amyloid cascade, membrane disruption/Aβ ion 
channel, mitochondrial abnormalities, energy deficits, glutamate excitotoxicity, 
cerebrovascular dysfunction, neuroinflammation, oxidative stress, Ca2+ dyshomeostasis and 
cytoskeletal aberrations. Each of these ideas were proposed and developed based on one or 
few particular pathological features of AD. As a consequence most of the currently favored 
hypotheses provide only a limited view rather than a more global perspective of the 
pathogenic mechanism. It also remains unclear what initial event(s) trigger the pathogenic 
cascade and how so many different pathological insults can be attributed to the key 
pathogenic event. 
Extensive autophagy involvement in AD has been well documented (Nixon et al., 2005; 
Shacka et al., 2008; Suzuki & Terry, 1967). However, it remains unsettled if autophagy plays 
a causative role, a protective role or is a consequence of the disease process itself (Ling & 
Salvaterra, 2009). Among the various signs and lesions of AD neuropathology, 
compromised autophagy-lysosomal vesicles and their resultant injuries appear to play a 
central role in initiating the pathogenic cascade leading to disease progression. Based on 
Drosophila models of AD and brain aging as well as growing evidence in this field, we have 
proposed an autophagy-derived neurodegenerative cascade initiated by Aβ1-42 and 
enhanced by aging (Ling & Salvaterra, 2009, 2011a; Ling et al., 2009).  
APP proteolysis and Aβ production occurs at membrane surfaces facing the lumen of 
membrane compartments including ER, Golgi apparatus and endosomal vesicles (Fiala, 2007; 
Gouras et al., 2005). Aβ is constitutively produced in human brains throughout the normal 
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lifespan. Apparently the levels of newly generated Aβ peptides may not be sufficient to initiate 
a pathogenic cascade in healthy neurons; however, due to their amphipathic property, they 
may disturb local membranes and the functional execution of host organelles. These 
organelles, if damaged, will be sequestered by autophagy. However, Aβ particularly Aβ1-42 
cannot be efficiently degraded in autophagy-lysosomal vesicles especially under chronic 
deterioration of this machinery during advancing age (Ling & Salvaterra, 2011a). Other 
indigestible proteins and lipids (for example lipofuscin) may synergistically contribute to the 
deterioration of autophagy-lysosomal machinery causing cargo storage in enlarged vesicles. 
Consistent with this view, intracellular Aβ peptides predominantly accumulate within 
autophagic and endosomal vesicles (Nixon, 2004; Takahashi et al., 2002; Yu et al., 2005) and 
AD-like neuropathological phenotypes are also seen in some lysosomal storage diseases (Bahr 
& Bendiske, 2002; Ohm et al., 2003; Jin et al., 2004; Settembre et al., 2008). 
Numerous lysosomal vesicles in cytosol would represent a large source of acidic contents 
and lysosomal hydrolases. The enlarged size and long-term retention of these vesicles may 
make them easily compromised especially when Aβ1-42 becomes concentrated within them. 
Compromised vesicles result in leakage of their acidic contents into cytosol. This will 
destabilize other intracellular structures and organelles including ER and mitochondria 
leading to oxidative stress and Ca2+ dyshomeostasis. The resultant damage from this altered 
intracellular microenvironment will further activate autophagy causing additional 
pathogenic stress. Thus a self-exacerbated pathogenic cascade is formed through initiation, 
dysfunction, compromise of autophagic vesicles and the resultant cytosolic chemical lesions. 
This neurodegenerative cascade is initiated by Aβ1-42 and enhanced by aging and eventually 
results in necrotic neuronal death. Once initiated, the cascade would likely become 
independent of continuous Aβ production since cytosolic chemical lesions would drive it as 
a progressive and irreversible pathogenic pathway. This autophagy-lysosomal-derived 
neurodegenerative cascade provides a common cellular framework for a detailed 
mechanistic understanding of the heterogeneous aspects of AD neuropathology as the signs, 
the lesions and the causes of the disease. 
4. Conclusion 
Alzheimer’s disease is an incurable terminal neurodegenerative disorder with multifactorial 
etiology and heterogeneous pathology. The clearer we understand the pathogenic 
mechanism(s) regarding its causes, lesions and signs, the better we should be able to 
develop effective treatments for mitigating or even preventing this disastrous disorder. The 
autophagy-lysosomal system, a bulk process for removal of intracellular toxic proteins and 
damaged organelles, appears to play a central role in the disease pathogenesis. Based on our 
recent work and a large volume of previous studies from other groups, we propose an 
autophagy-lysosomal cascade that is attributable to various AD etiologies, and responsible 
for the hierarchical pathological signs and pathogenic lesions. One of the prominent features 
of this pathogenic mechanism is its potential for self-exacerbation. Once progressing to an 
uncontrollable stage, this cascade is likely to be independent of initial contributions from 
causative factors and will continue to develop progressively and irreversibly. This feature 
fits well with the onset of pathological and clinical AD. It has never been clear when the 
disease pathology actually starts; however, once diagnosed, the disease develops 
progressively and relentlessly. This feature emphasizes the importance of preventative 
strategies applied to the at-risk individuals prior to the actual occurrence of this disease. 
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The autophagy-lysosomal cascade for AD pathogenesis appears to provide a unified cellular 
framework for understanding the disease; however, therapeutic development targeting 
autophagy-lysosomal pathway is far from maturation. Our knowledge of the autophagy-
lysosomal system is fast growing (Klionsky, 2007). Many basic aspects of the pathway are 
still waiting for detailed characterization. A beneficial outcome from manipulation of 
autophagy activity under neurodegenerative conditions is still uncertain. Even though basal 
autophagy is protective and autophagy induction has prosurvival effects observed in some 
disease models (Rubinsztein et al., 2007), detrimental effects of increased autophagy are also 
associated with certain pathological conditions (Cherra et al., 2010; White & DiPaola, 2009). 
Our studies, however, emphasize that enhancing the maintenance of an integrated and 
efficient autophagy–lysosomal system in brain rather than simply induction of autophagy 
activity would be a promising therapeutic direction for anti-aging or prevention of AD. 
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